Decreased CD4+ T cell expression of L-Selectin (CD62L), a molecule implicated in leukocyte adhesion to the endothelium, during natalizumab treatment was found to associate with an increase of PML risk (25). This evidence concerns the gene CD4 and progressive multifocal leukoencephalopathy.